Bruker (BRKR) executive exercises options and sells 2,000 shares

Rhea-AI Filing Summary

Bruker Corp executive Mark Munch reported option exercises and a share sale. On February 13, he exercised stock options for 2,000 shares, converting derivative securities into common stock at a price of $22.19 per share. He then sold 2,000 common shares at $36.94 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan.

Following these transactions, he directly owned 128,443 shares of Bruker common stock and held 14,000 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Munch Mark

(Last) (First) (Middle)

BRUKER CORPORATION

40 MANNING ROAD

(Street)

BILLERICA MA 01821

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRUKER CORP [ BRKR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC VP&PRES BRUKER NANO INC.

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		2,000	A	$22.19	130,443	D
Common Stock	02/13/2026		S		2,000(1)	D	$36.94	128,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Purchase)	$22.19	02/13/2026		M			2,000	(2)	10/04/2026	Common Stock	2,000	$0	14,000	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The stock option granted to the Reporting Person on October 4, 2016 (the "Original Grant Date") vests on the first, second, third and fourth anniversaries of the Original Grant Date.

	/s/ Michael Simone, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mark Munch report for BRKR?

Mark Munch reported exercising stock options for 2,000 shares and selling 2,000 Bruker common shares. The option exercise converted derivative securities into stock, and the sale was an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.

At what prices did Mark Munch trade Bruker (BRKR) shares?

Mark Munch’s option exercise converted into common stock at $22.19 per share, and he sold 2,000 Bruker common shares at $36.94 per share. These prices reflect the exercise and sale terms reported for the February 13 transactions.

How many Bruker (BRKR) shares does Mark Munch own after these trades?

After the reported trades, Mark Munch directly owns 128,443 shares of Bruker common stock. He also holds 14,000 stock options, reflecting his remaining derivative-based equity position as disclosed in the Form 4 filing.

Were Mark Munch’s Bruker (BRKR) share sales under a 10b5-1 plan?

Yes, the Form 4 notes the sales were effected under a Rule 10b5-1 trading plan. Such plans allow insiders to pre-schedule trades, providing a structured way to sell shares over time while managing potential conflicts with material nonpublic information.

What role does Mark Munch hold at Bruker (BRKR)?

Mark Munch is an executive officer of Bruker, serving as Executive Vice President and President of Bruker Nano Inc. His Form 4 filing reflects equity transactions related to this leadership role, including stock option exercises and subsequent share sales.